Search results for "OLED"

showing 10 items of 349 documents

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis…

2020

BACKGROUND: Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents.

Malebody-mass indexADULTHOODAdolescentspituuskasvuPediatricsBody Mass Index0302 clinical medicineChild DevelopmentnuoretPublic health surveillanceMedicineHealth Status Indicators10. No inequalityChild11 Medical and Health SciencesBody mass indexComputingMilieux_MISCELLANEOUSeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801General MedicineBody mass indexeskansainvälinen vertailu3. Good healthGeographyHealth030220 oncology & carcinogenesisChild PreschoolMedical and Health sciences//purl.org/becyt/ford/3 [https]medicine.medical_specialtySchool-aged adolescentsSocio-culturalelapset (ikäryhmät)Nursing.territoriesravinto//purl.org/becyt/ford/3.3 [https]03 medical and health sciencesSchool ChildrenSDG 3 - Good Health and Well-beingSYSTEMATIC ANALYSISHumansschool-aged children and adolescentsMontenegroeducationScience & TechnologyOmvårdnadHealth sciences Medical and Health sciencesCiências médicas e da saúdeBayes TheoremAnthropometryAdolescent Developmentmedicine.diseaseTRENDSHeight and Body-mass IndexFaculdade de Ciências SociaisUNDERNUTRITIONHeight index trajectoriesHeight body mass index children epidemiologybody-mass index; school-aged children and adolescents; risk factors growthStatureBody mass indexDemographySettore MED/09 - Medicina InternaInternationality[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyBody-mass index trajectoriesEpidemiologyMedicine and Health Sciencesrisk factorscountriesEPIDEMIOLOGYheight ; body-mass index ; children ; adolescents ; BMI030212 general & internal medicinepainoindeksiChild development2. Zero hungerMedicine(all)School age childobestity children cardiovascularPopulation Health1. No povertyPediatrikPublic Health Global Health Social Medicine and Epidemiology3142 Public health care science environmental and occupational healthPeer reviewPooled analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNUTRITIONFemalemedicine.symptompooled analysis/dk/atira/pure/subjectarea/asjc/2700Life Sciences & Biomedicineterveysheight BMI nutrition health children adolescentsAdolescentgrowthPopulationbody-massPopulation basedBody-mass indexBMIYoung AdultMedicine General & InternalchildrenMeta-Analysis as TopicGeneral & Internal Medicineparasitic diseasesWeight gainSchool-aged childrensAge trajectoriesbusiness.industryHeightWeightBody HeightFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionONSETCiências da Saúde Ciências médicas e da saúdeSchool-aged childrenVDP::Medical disciplines: 700::Health sciences: 800::Community medicine Social medicine: 801businessWeight gainterveysriskitEstilos de Vida e Impacto na Saúde
researchProduct

Endoscopic papillary large balloon dilation in patients with large biliary stones and periampullary diverticula: Results of a multicentric series.

2018

Abstract Introduction Stone extraction represents the most frequent indication for endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic papillary large balloon dilation (EPLBD) is a recent introduced approach consisting of an endoscopic papillary large balloon dilation following limited endoscopic sphyncterotomy (ES), which has been proven to be safe and effective for extraction of large common bile duct (CBD) stones. Peri-ampullary diverticula (PAD) are described in 10–20% of patients undergoing ERCP. Aim of our study is to evaluate efficacy and safety of EPLBD for the extraction of large biliary stones in patients with PAD. Methods The prospectively collected endoscopy databa…

Malemedicine.medical_specialtyAmpulla of VaterDilation assisted stone extractionTherapeutic ERCPEndoscopic papillary large balloon dilationGallstonesDASE Dilation assisted stone extraction Difficult choledocholithiasis03 medical and health sciencesSphincterotomy Endoscopic0302 clinical medicineInternal medicinemedicineStone extractionHumansLarge bile duct stoneIn patientAgedRetrospective StudiesAged 80 and overCholangiopancreatography Endoscopic RetrogradeEndoscopic retrograde cholangiopancreatographyHepatologyCommon bile ductmedicine.diagnostic_testbusiness.industryGastroenterologyDASEHepatologyMiddle AgedDilatationSurgeryEndoscopyDiverticulummedicine.anatomical_structureLogistic ModelsTreatment OutcomeItalyDifficult choledocholithiasi030220 oncology & carcinogenesisBalloon dilation030211 gastroenterology & hepatologyFemaleEPLBDbusinessBILIARY STONESDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers

2005

Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patient…

Malemedicine.medical_specialtyBone diseasemedicine.medical_treatmentPainBone NeoplasmsGastroenterologyBone resorptionBone remodelingProstate cancerzoledronic acidInternal medicinemedicineHumansPharmacology (medical)Bone ResorptionInfusions Intravenousbone metastaseAgedPain MeasurementPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesProstatic NeoplasmsMiddle AgedBisphosphonatemedicine.diseaseprostate cancerSurgeryRadiation therapyBone Density Conservation AgentsInfectious DiseasesZoledronic acidOncologybone metabolism biomarkerbusinessBiomarkersmedicine.drug
researchProduct

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid…

2017

Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program af…

Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Association between periodontal disease and prostate cancer: a systematic review and meta-analysis

2021

Background Periodontal disease is a chronic infectious disease caused by bacterial infection which may lead to various systematic diseases. Recently, increasing studies have explored the correlation of periodontal disease with the risk of prostate cancer. However, the findings were inconsistent. Hence, this study aims to investigate the association between periodontal disease and the risk of prostate cancer by a meta-analysis. Material and Methods PubMed, EMBASE, and Cochrane were searched for publications up to July 17, 2020. Cohort and case-control studies evaluating the risk of prostate cancer in patients with periodontal disease were included. A fixed or random-effect model was used to …

Malemedicine.medical_specialtyMEDLINEReviewCohort Studieszoledronic acid03 medical and health sciencesProstate cancer0302 clinical medicinePeriodontal diseaseRisk FactorsInternal medicineHumansMedicinePeriodontologyIn patientbisphosphonatesGeneral DentistryPeriodontal DiseasesUNESCO:CIENCIAS MÉDICASbusiness.industryProstatic Neoplasmsdenosumab030206 dentistrymedicine.diseaseConfidence intervalosteonecrosis of the jawOtorhinolaryngologyCase-Control StudiesMeta-analysisRelative riskCohortincidenceSurgerybusinessantiangiogenic drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate can…

2012

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; Published data demonstrated that zoledronic acid (ZOL) exhibits antiangiogenetic effects. A promising tool for monitoring antiangiogenic therapies is the measurement of circulating endothelial cells (CECs) and circulating endothelial precursor cells (CEPs) in the peripheral blood of patients. Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Ten consecutive patients with a histologic diagnosis of low-risk prostate adenocarcinoma were enrolled and received an intravenous infusion of ZOL at baseline (T0), 28 days (T28) and 56 days (T56). Blood samp…

Malemedicine.medical_specialtyPathologyCancer ResearchBone Density Conservation AgentAngiogenesismedicine.medical_treatmentUrologyAngiogenesis InhibitorsAngiogenesis; Circulating endothelial cells; Circulating endothelial precursor cells; Prostate cancer; Zoledronic acid; Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Medicine (all); Oncology; Cancer ResearchFlow cytometryProstate cancerCirculating endothelial cellCell MovementStem CellPrecursor cellMedicineHumansImidazoleNeoadjuvant therapyZoledronic acidAgedEndothelial CellProstate cancermedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryStem CellsMedicine (all)ImidazolesEndothelial CellsProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePeripheral bloodNeoadjuvant TherapyAngiogenesiZoledronic acidDiphosphonateOncologyCirculating endothelial precursor cellProstatic NeoplasmStem cellbusinessmedicine.drugAngiogenesis InhibitorHuman
researchProduct

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network …

2020

Background Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network (“Rete Oncologica Piemonte e Valle d’Aosta”), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. Material and Methods MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cas…

Malemedicine.medical_specialtyPopulation03 medical and health sciencescheek refinement0302 clinical medicineBreast cancerplasticInternal medicinemedicineCarcinomaHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective Studiesbuccal fat padeducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchIncidence (epidemiology)Cancer030206 dentistrymedicine.diseaseDenosumabZoledronic acidItalyOtorhinolaryngologyaestheticsfacial silhouette refiningbuccal fat pad excisionBisphosphonate-Associated Osteonecrosis of the JawSurgeryMultiple MyelomaOsteonecrosis of the jawbusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Endoscopic treatment of the "sump syndrome" after choledochoduodenostomy: a new technique using an amplatzer septal occluder.

2006

A 58-year-old male patient had been suffering for 35 years from recurrent cholangitis, biliary sludge and infection-induced stone formation after open cholecystectomy because of empyema of the gallbladder and severe acute and delayed postoperative complications. The pathophysiological origin of this chronic "sump syndrome" was a choledochoduodenostomy which had been performed prophylactically at the time of the initial operation. The patient agreed to an experimental treatment option with use of an Amplatzer atrial-septal defect (ASD) occluder for closure of the symptomatic choledochoduodenal fistula. The double-disc occluder was introduced through a 9 French diameter and 90 cm long sheath …

Malemedicine.medical_specialtyPostcholecystectomy syndromeFistulamedicine.medical_treatmentSump SyndromeProsthesis DesignProsthesis ImplantationLiver Function TestsmedicineHumansBiliary sludgeDuodenoscopyCholangiopancreatography Endoscopic RetrogradeCommon bile ductbusiness.industryGallbladderGastroenterologyMiddle Agedmedicine.diseaseEmpyemaSurgerymedicine.anatomical_structureTreatment OutcomeTherapeutic endoscopyCholedochostomyFluoroscopybusinessPostcholecystectomy SyndromeFollow-Up StudiesZeitschrift fur Gastroenterologie
researchProduct

Orthotopic Liver Transplantation: T-Tube or Not T-Tube? Systematic Review and Meta-Analysis of Results

2009

Background The purpose of this study was to compare outcomes after duct-to-duct anastomoses with or without biliary T-tube in orthotopic liver transplantation. Methods We pooled the outcomes of 1027 patients undergoing choledocho-choledochostomy with or without T-tube in 9 of 46 screened trials by means of fixed or random effects models. Results The "without T-tube" and "with T-tube" groups had equivalent outcomes for: anastomotic bile leaks or fistulas, choledocho-jejunostomy revisions, dilatation and stenting, hepatic artery thromboses, retransplantation, and mortality due to biliary complications. The "without T-tube" group had better outcomes when considering "fewer episodes of cholangi…

Malemedicine.medical_specialtyQuality Assurance Health Caremedicine.medical_treatmentPeritonitisGallbladder DiseasesPeritonitisLiver transplantationAnastomosisPostoperative ComplicationsOdds RatiomedicineHumansRetrospective StudiesTransplantationbusiness.industryIncidence (epidemiology)Anastomosis SurgicalRetrospective cohort studyOdds ratioRandom effects modelmedicine.diseaseLiver TransplantationSurgeryCholedochostomyMeta-analysisPractice Guidelines as TopicDisease ProgressionFemalebusinessTransplantation
researchProduct